Clinical trial · Interventional
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Graft Versus Host Disease | — | UNRESOLVED | — |
| Chronic Graft Versus Host Disease | — | UNRESOLVED | — |
| Hematopoietic and Lymphatic System Neoplasm | Hematopoietic and Lymphatic System Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dental Cleaning | Procedure | — | UNRESOLVED |
| Dental Plaque sampling | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Prevention (dental cleaning)
- description
- Patients undergo simplified dental cleaning on day +28 following HCT.
- interventionNames
- Procedure: Dental Cleaning
- Procedure: Dental Plaque sampling
Primary outcomes (1)
- measure
- Probability of moderate-to-severe chronic graft versus host disease
- timeFrame
- At 1-year post-transplant
Secondary outcomes (3)
- measure
- Probability of grade III-IV acute graft versus host disease
- timeFrame
- At 6-months post-transplant
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years old * T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed * One of the following HCT donor types: * 9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor * Cord blood * Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH) * Ability to understand and sign a written informed consent document (or legal representative) Exclusion Criteria: * Edentulous state * Bone marrow as graft source * Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis * Use of anti-thymocyte globulin (ATG) in conditioning
References
Publications (0)
Data not yet available